Immunocore and GlaxoSmithKline Select First ImmTAC Clinical Candidate in Discovery Collaboration

Immunocore Limited, a world-leading biotechnology company developing novel T cell receptor (TCR) based biological drugs to treat cancer, viral infections and autoimmune disease, today announced that GlaxoSmithKline (GSK) has selected the first clinical candidate as part of a discovery collaboration, resulting in an undisclosed milestone payment to Immunocore.

The candidate selected ImmTAC addresses a target relevant in a number of different cancer indications including synovial sarcoma, bladder and non-small cell lung (NSCL) cancers. Immunocore will now undertake further preclinical testing and cGMP manufacture before progressing the ImmTAC to Phase I clinical development.